Hunan Jiudian Pharmaceutical Past Earnings Performance
Past criteria checks 5/6
Hunan Jiudian Pharmaceutical has been growing earnings at an average annual rate of 39.6%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 26.7% per year. Hunan Jiudian Pharmaceutical's return on equity is 21.3%, and it has net margins of 17.2%.
Key information
39.6%
Earnings growth rate
38.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 26.7% |
| Return on equity | 21.3% |
| Net Margin | 17.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Hunan Jiudian Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,945 | 508 | 1,373 | 264 |
| 30 Jun 24 | 2,841 | 455 | 1,354 | 277 |
| 31 Mar 24 | 2,782 | 417 | 1,415 | 252 |
| 31 Dec 23 | 2,693 | 368 | 1,413 | 254 |
| 30 Sep 23 | 2,620 | 371 | 1,380 | 230 |
| 30 Jun 23 | 2,513 | 338 | 1,378 | 208 |
| 31 Mar 23 | 2,379 | 291 | 1,298 | 210 |
| 01 Jan 23 | 2,326 | 270 | 1,298 | 201 |
| 30 Sep 22 | 2,097 | 243 | 1,149 | 184 |
| 30 Jun 22 | 1,927 | 221 | 1,050 | 174 |
| 31 Mar 22 | 1,799 | 214 | 991 | 157 |
| 01 Jan 22 | 1,628 | 204 | 884 | 146 |
| 30 Sep 21 | 1,451 | 196 | 791 | 113 |
| 30 Jun 21 | 1,317 | 162 | 733 | 103 |
| 31 Mar 21 | 1,096 | 122 | 608 | 91 |
| 31 Dec 20 | 978 | 82 | 551 | 82 |
| 30 Sep 20 | 921 | 72 | 504 | 91 |
| 30 Jun 20 | 891 | 59 | 464 | 98 |
| 31 Mar 20 | 906 | 52 | 448 | 110 |
| 31 Dec 19 | 924 | 55 | 447 | 110 |
| 30 Sep 19 | 900 | 65 | 401 | 99 |
| 30 Jun 19 | 867 | 73 | 376 | 85 |
| 31 Mar 19 | 811 | 70 | 352 | 64 |
| 31 Dec 18 | 801 | 72 | 336 | 57 |
| 30 Sep 18 | 746 | 67 | 314 | 46 |
| 30 Jun 18 | 680 | 72 | 249 | 47 |
| 31 Mar 18 | 613 | 71 | 208 | 37 |
| 31 Dec 17 | 535 | 69 | 170 | 29 |
| 30 Sep 17 | 472 | 72 | 131 | 19 |
| 30 Jun 17 | 430 | 62 | 143 | 0 |
| 31 Mar 17 | 385 | 56 | 128 | 0 |
| 31 Dec 16 | 376 | 55 | 127 | 0 |
| 30 Sep 16 | 334 | 39 | 123 | 0 |
| 30 Jun 16 | 320 | 38 | 119 | 0 |
| 31 Mar 16 | 305 | 41 | 110 | 0 |
| 31 Dec 15 | 290 | 45 | 101 | 0 |
| 30 Sep 15 | 281 | 43 | 98 | 0 |
| 30 Jun 15 | 272 | 40 | 95 | 0 |
| 31 Mar 15 | 269 | 41 | 92 | 0 |
| 31 Dec 14 | 266 | 41 | 89 | 0 |
| 31 Dec 13 | 241 | 36 | 90 | 0 |
Quality Earnings: 300705 has high quality earnings.
Growing Profit Margin: 300705's current net profit margins (17.2%) are higher than last year (14.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300705's earnings have grown significantly by 39.6% per year over the past 5 years.
Accelerating Growth: 300705's earnings growth over the past year (36.8%) is below its 5-year average (39.6% per year).
Earnings vs Industry: 300705 earnings growth over the past year (36.8%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 300705's Return on Equity (21.3%) is considered high.